Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells

Expert Review of Proteomics

Volumn 3, Issue 6, 2006, Pages 641-652

  Wahl, Angela ^a   Weidanz, Jon ^b   Hildebrand, William ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Affinity purification; Cancer; Cell pharm; Class I molecule; Cytotoxic T lymphocyte; Epitope; Human leukocyte antigen; Mass spectrometry; Soluble human leukocyte antigen; Virus infected

Indexed keywords

HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

CANCER CELL; CYTOTOXIC T LYMPHOCYTE; HUMAN; MASS SPECTROMETRY; PEPTIDE MAPPING; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REPRODUCIBILITY; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; NEOPLASMS; PEPTIDES; PROTEOMICS; VIRUS DISEASES;

EID: 33845867675     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.6.641     Document Type: Review

References (64)

1. Terhorst C, Parham P, Mann DL, Strominger JL. Structure of HLA antigens: amino acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc. Natl Acad. Sci. USA 73(3), 910-914 (1976).
2. Rock KL, Gramm C, Rothstein L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78(5), 761-771 (1994).
3. Garcia K, Degano M, Pease LR et al. Structural basis of plasticity in T-cell receptor recognition of a self peptide-MHC antigen. Science 279(5354), 1166-1172 (1998).
4. Robinson J, Marshall M, Parham P et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res. 31(1), 311-314 (2003).
5. Krahenbuhl O, Rey C, Jenne D et al. Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J. Immunol. 141(10), 3471-3477 (1988).
6. Sandberg J, Fast N, Nixon D. Functional heterogeneity or cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J. Immunol. 167(1), 181-187 (2001).
7. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 272(5276), 723-725 (1996).
8. Stevanovic S. Antigen processing is predictable: from genes to T cell epitopes. Transpl. Immunol. 14(3-4), 171-174 (2005).
9. Parker KC, Bednarek M, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding individual peptide side-chains. J. Immunol. 152(1), 163-175 (1994).
10. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999).
11. Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histomcompatibility complex molecules. J. Mol. Biol. 267(5), 1258-1267 (1997).
12. Peters B, Tong W, Sidney J, Sette A, Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-1 molecules. Bioinformatics 19(14), 1765-1772 (2003).
13. Altuvia Y, Margalit H. A structure-based approach for prediction of MHC-binding peptides. Methods 34(4), 454-459 (2004).
14. Segal MR, Cummings M, Hubbard AE. Relating amino acid sequence to phenotype: analysis of peptide-binding data. Bioinformatics 57(2), 632-642 (2001).
15. Lim JS, Kim S, Lee HG, Lee KY, Kwon TJ, Kim K. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modeling. Mol. Immunol. 33(2), 221-230 (1996).
16. Kesmir C, Nussbaum A, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 15(4), 287-296 (2002).
17. Reche PA, Glutting J, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol. 63(9), 701-709 (2002).
18. Hakenberg J, Nussbaum A, Schild H et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics 2(3), 155-158 (2003).
19. Tenzer S, Peters B, Bulik S et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62(9), 1025-1037 (2005).
20. Kessler JH, Mommaas B, Mutis T et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 64(2), 245-255 (2003).
21. van der Burg SH, Visseren M, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156(9), 3308-3314 (1996).
22. Ottenhoff TH, Geluk A, Toebes M, Benckhuijsen WE, van Meijgaarden KE, Drijfhout JW. A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. J. Immunol. Methods 200(1-2), 88-97 (1997).
23. Parker KC, Carreno B, Sestak L, Utz U, Biddison WE, Coligan JE. Peptide binding to HLA-A2 and HLA-B27 isolated from Escherichia coli. J. Biol. Chem. 267(8), 5451-5459 (1992).
24. Feltkamp MC, Vierboom M, Kast WM, Melief CJ. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol. Immunol. 31(18), 1391-1401 (1994).
25. Parkhurst MR, Riley J, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10(14), 4688-4698 (2004). • Cytotoxic T cells isolated from patients immunized with human leukocyte antigen (HLA) A*0201 ligand human telomerase reverse transcriptase (hTERT):540-548 failed to generate a response against cancer cells expressing hTERT in vitro, suggesting that the peptide is not HLA class I presented on the surface of cancer cells.
26. Dutoit V, Taub R, Papadapoulos KP et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 110(12), 1813-1822 (2002).
27. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180(1), 347-352 (1994).
28. Tsai V, Southwood S, Sidney J et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158(4), 1796-1802 (1997).
29. Yang OO, Kalams S, Rosenzweig M et al. Efficient lysis of human immunodeficiency virus type-1 infected cells by cytotoxic T lymphocytes. J. Virol. 70(9), 5799-5806 (1996).
30. Viatte S, Alves P, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. Immunol. Cell Biol. 84 (3), 318-330 (2006).
31. Townsend A, Bastin J, Gould K et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168(4), 1211-1224 (1988).
32. Minev B, Hipp J, Firat H, Schmidt J, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97(9), 4796-4801 (2000).
33. Vonderheide R, Hahn W, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10(6) 673-679, (1999).
34. Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31(9), 2642-2651 (2001).
35. Lemmel C, Stevanovic S. The use of HPLC-MS in T-cell epitope identification. Methods 29(3), 248-259 (2003).
36. Wallny HJ, Deres K, Faath S et al. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int. Immunol. 4(10), 1085-1090 (1992).
37. Christinck ER, Luscher M, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352(6330), 67-70 (1991).
38. Hunt DF, Henderson R, Shabanowitz J et al. Characterization of peptides bound to the class I molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1363 (1992).
39. Turnquist HR, Schenk E, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics 53(10-11), 830-834 (2002).
40. Barnea E, Beer I, Patoka R et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32(1), 213-222 (2002).
41. Bettinotti MP, Hadzikadic L, Ruppe E, Dhillon G, Stroncek DS, Marincola FM. New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology. J. Immunol. Methods 279(1-2), 143-148 (2003).
42. Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W. Large-scale production of class I bound peptides: assigning a signature to HLA'-hB*1501. Immunogenetics 45(6), 379-385 (1997).
43. Hickman HD, Batson C, Prilliman KR, Crawford DL, Jackson KL, Hildebrand WH. C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum. Immunol. 61(12), 1339-1346 (2000).
44. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324), 290-296 (1991).
45. Toes RE, Nussbaum AK, Degermann S et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194(1), 1-12 (2001).
46. Buchli R, VanGundy R, Giberson CF, Hildebrand WH. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J. Immunol. Methods 314(1-2) 38-53, (2006).
47. Anderson MLM, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand. J. Immunol. 57(1), 21-27 (2003).
48. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153(12), 5586-5592 (1994).
49. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J. Immunol. 167(2), 787-796 (2001).
50. Skipper JC, Gulden P, Hendrickson RC et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82(5), 669-677 (1999). •• Presence of HLA class I melanoma epitopes on the surface of melanoma cells, discovered by reverse-immunological techniques confirmed by direct discovery.
51. Hofmann S, Glückmann M, Kausche S et al. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol. Cell Proteomics 4(12), 1888-1897 (2005).
52. Krämer BF, Schoor O, Kruger T et al. MAGED4-Expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 4(9), 943-948 (2005).
53. van Els CA, Herberts C, van der Heeft E et al. A single naturally processed measles virus peptide fully dominates the HLA-A* 0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30(4), 1172-1181 (2000). •• Three class I HLA measles-derived peptides are identified by comparing peptide pools acid eluted from class I molecules purified from uninfected and measles-infected cells.
54. Rotzschke O, Falk K, Deres K et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348(6298) 252-254 (1990). • One of the earliest accounts of direct epitope discovery uncovered multiple influenza-derived peptides acid eluted from purified mouse major histocompatibility complex (MHC) class I molecules H-2-Db and H-2-Kd upon infection with Influenza A/PR/8/34 virus.
55. Herberts CA, Meiring H, van Gaans-van den Brink JA et al. Dynamics of measles virus protein expression are reflected in the MHC class I epitope display. Eur. J. Immunol. 39(10), 567-575 (2003).
56. di Marzo Veronese F, Arnott D, Barnaba V et al. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. J. Exp. Med. 183(6), 2509-2516 (1996). •• Comparison of HLA class I peptides purified from HIV-1 infected and uninfected cells by liquid chromatography/mass spectrometry (LC/MS) identified three vinculin-derived class I peptides as unique to HIV-1-infected cells.
57. Herberts CA, van Gaans-van den Brink JA, van der Heeft E et al. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum. Immunol. 64(1), 44-55 (2003). •• MS of class I peptides unique to and upregulated during measles virus infection identified two abundant self-derived peptides that generate a cytotoxic T-lymphocyte response in acutely infected patients.
58. Hickman HD, Luis A, Bardet W et al. Cutting edge: class I presentation of host peptides following HIV infection. J. Immunol. 171(1), 22-26 (2003). •• Several host-derived HLA class I peptides eluted from recombinant HLA class I secretion (sHLA) molecules exhibiting increased presentation during HIV-1 infection were identified by MS and MS/MS.
59. Loriot A, de Plaen E, Boon T, de Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem. 281(15) 10118-10126 (2006).
60. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6(6), 715-726 (1997).
61. Wittman V, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J. Immunol. 177(6) 4187-4195 (2006).
62. Sercarz EE, Lehmann P, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766 (1993).
63. Celis E. Getting peptide vaccines to work: just a matter of quality control? J. Clin. Invest. 110(12), 1765-1768 (2002).
64. Crowe SR, Turner S, Miller SC et al. Differential antigen presentation regulates the changing patterns of CD8+T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198(3) 339-410 (2003).